by | Sep 27, 2016 8:33 pm | Medical Devices
In the first eight months of 2016, 80 transactions were announced in the Medical Device sector, making it unlikely this year’s deal volume would surpass last year’s total of 114 deals. As the third quarter wraps up, the sector’s deal volume has reached 90 deals: 31 in Q1, 27 in Q2, and 32 as of September 27th in Q3. If that deal making pace continues through Q4, at 2016’s average rate of 30 deals a quarter, we’ll see a 5% increase in deal volume since last year. September’s medical device deals include interventional device maker Boston Scientific Corporation (NYSE: BSX), which acquired EndoChoice Holdings Inc. (NYSE: GI), maker of endoscopic imaging systems, devices and infection control... Read More »
by | Sep 15, 2016 6:28 pm | Medical Devices, Private Equity
For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million. Halfway through September, the company has made two more acquisitions, for undisclosed prices. For those keeping score, that’s eight deals for approximately $4.1 billion. Stryker’s most recent deals have targeted Ivy Sports Medicine, LLC for its minimally invasive meniscal repair platform, and Restore... Read More »
by | Sep 9, 2016 3:23 pm | Medical Devices
Mergers and acquisitions in the medical device segment has been a bit sluggish this year. Even with two deals announced on September 1, marking 79th and 80th sector transactions in 2016, there is a lot of ground to make up to match the 114 deals announced in 2015. Stryker Corporation (NYSE: SYK) announced its seventh acquisition this year, paying an undisclosed amount for Ivy Sports Medicine, LLC. Ivy Sports Medicine provides medicine therapies for orthopedic surgeons and patients through its comprehensive minimally invasive meniscal repair platform. It includes the only FDA-approved collagen meniscus implant (CMI®) on the market. Ivy’s history and sole focus on advancing the... Read More »
by | Aug 30, 2016 6:01 pm | Biotechnology, Medical Devices
Microbot Medical Ltd., an Israel-based medical device company that specializes in the research, design, development and commercialization of micro-robotics-assisted medical technologies, has merged with StemCells Inc. (NASDAQ: STEM), a biotech firm that engages in the research, development, and commercialization of stem cell-based therapeutics for the treatment of central nervous system diseases. For StemCells, this merger is a strategic alternative to its failed Phase 2 clinical study of human neural stem cells in chronic spinal cord injuries. The combined company will pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal... Read More »
by | Aug 5, 2016 1:06 pm | Medical Devices
With five acquisitions in the infection prevention/disposables market since 2014, Cantel Medical (NYSE: CMN) is on a roll. The company, which provides infection prevention and control product and services, just announced its second medical device deal this year, buying Accutron Inc., a privately-held manufacturer of nitrous oxide delivery systems and single-use nasal masks. The $52.5 million acquisition will expand the dental portfolio of Crosstex International, Cantel’s Healthcare Disposables segment, adding a branded, single-use disposable product line. The acquisition marks Cantel’s entry into the dental equipment market. In February 2016, Cantel acquired the Sterility... Read More »
by | Jul 18, 2016 2:09 pm | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation
Uncertainty is the hobgoblin of the merger and acquisition markets, and the month of June was a high point (or low point, depending on your perspective) for anxiety in global financial markets. Still, the healthcare deals kept rolling in. Our preliminary total for June 2016 stands at 115 transactions, exactly equal with the same month a year ago. Compared with May’s total of 141 deals, though, June’s total does look as if someone is applying the brakes. It takes 12 months to make a year, though, and one month’s results do not create a trend. The digital health sector turned in the strongest gain compared with June 2015, when only two deals were announced. This June, 22 deals were announced... Read More »